Rosa Ana Risques

Rosa Ana Risques

Auto-generated profile, based on publicly available information

Rosa Ana Risques

Department of Laboratory Medicine and Pathology, University of Washington, Seattle, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2018 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
RRRosa Ana Risques
Rosa Ana Risques
SKScott R Kennedy
Scott R Kennedy
DNA mutations are inevitable. Despite proficient DNA repair mechanisms, somatic cells accumulate mutations during development and aging, generating cells with different genotypes within the same individual, a phenomenon known as somatic mosaicism. While the existence of somatic mosaicism has long been recognized, in the last five years, advances in sequencing have provided unprecedented resolution to characterize the extent and nature of somatic genetic variation. Collectively, these new studies are revealing a previously uncharacterized aging phenotype: the accumulation of clones with cancer driver mutations. Here, we summarize the most recent findings, which converge in the novel notion that cancer-associated mutations are prevalent in normal tissue and accumulate with aging.

5 May 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JKJeffrey D. Krimmel
Jeffrey D. Krimmel
MSMichael W. Schmitt
Michael W. Schmitt
MHMaria I. Harrell
Maria I. Harrell
KAKathy J. Agnew
Kathy J. Agnew
SKScott R. Kennedy
Scott R. Kennedy
RRRosa Ana Risques
Rosa Ana Risques
Significance: The detection of rare tumor-specific somatic mutations in “liquid biopsies” is limited by the high error rate of DNA sequencing technologies. By sequencing peritoneal fluid from women with high-grade serous ovarian cancer, we demonstrate that duplex sequencing, currently the most accurate sequencing technology, is able to detect one cancer cell among tens of thousands of normal cells. This unprecedented sensitivity also revealed a striking prevalence of extremely low frequency TP53 mutations in normal tissue. Women with and without cancer harbored TP53 mutations of pathogenic consequences, both in peritoneal fluid and peripheral blood. These mutations likely represent a premalignant mutational background that accumulates in cancer and aging.

1 July 2019 in Cell Reports
Verified
Journal Article
Open access
JSJesse J. Salk
Jesse J. Salk
KLKaitlyn Loubet-Senear
Kaitlyn Loubet-Senear
EMElisabeth Maritschnegg
Elisabeth Maritschnegg
CVCharles C. Valentine
Charles C. Valentine
LWLindsey N. Williams
Lindsey N. Williams
RRRosa Ana Risques
Rosa Ana Risques
High-accuracy next-generation DNA sequencing promises a paradigm shift in early cancer detection by enabling the identification of mutant cancer molecules in minimally invasive body fluid samples. We demonstrate 80% sensitivity for ovarian cancer detection using ultra-accurate Duplex Sequencing to identify TP53 mutations in uterine lavage. However, in addition to tumor DNA, we also detect low-frequency TP53 mutations in nearly all lavages from women with and without cancer. These mutations increase with age and share the selection traits of clonal TP53 mutations commonly found in human tumors. We show that low-frequency TP53 mutations exist in multiple healthy tissues, from newborn to centenarian, and progressively increase in abundance and pathogenicity with older age across tissue types. Our results illustrate that subclonal cancer evolutionary processes are a ubiquitous part of normal human aging, and great care must be taken to distinguish tumor-derived from age-associated mutations in high-sensitivity clinical cancer diagnostics.

22 August 2019 in Trends in Cancer
Verified
Journal Article
Closed access
SKScott R. Kennedy
Scott R. Kennedy
YZYuezheng Zhang
Yuezheng Zhang
RRRosa Ana Risques
Rosa Ana Risques

16 February 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
JMJulia Matas
Julia Matas
BKBrendan Kohrn
Brendan Kohrn
JFJeanne Fredrickson
Jeanne Fredrickson
KCKelly Carter
Kelly Carter
MYMing Yu
Ming Yu
RRRosa Ana Risques
Rosa Ana Risques
Although somatic mutations in colorectal cancer are well characterized, little is known about the accumulation of cancer mutations in the normal colon before cancer. Here, we have developed and applied an ultrasensitive, single-molecule mutational test based on CRISPR-DS technology, which enables mutation detection at extremely low frequency (<0.001) in normal colon from patients with and without colorectal cancer. This testing platform revealed that normal colon from patients with and without colorectal cancer carries mutations in common colorectal cancer genes, but these mutations are more abundant in patients with cancer. Oncogenic KRAS mutations were observed in the normal colon of about one third of patients with colorectal cancer but in none of the patients without colorectal cancer. Patients with colorectal cancer also carried more TP53 mutations than patients without cancer and these mutations were more pathogenic and formed larger clones, especially in patients with early-onset colorectal cancer. Most mutations in the normal colon were different from the driver mutations in tumors, suggesting that the occurrence of independent clones with pathogenic KRAS and TP53 mutations is a common event in the colon of individuals who develop colorectal cancer. These results indicate that somatic evolution contributes to clonal expansions in the normal colon and that this process is enhanced in individuals with cancer, particularly in those with early-onset colorectal cancer. Significance: This work suggests prevalent somatic evolution in the normal colon of patients with colorectal cancer, highlighting the potential of using ultrasensitive gene sequencing to predict disease risk.

15 January 2018 in Philosophical Transactions of the Royal Society B: Biological Sciences
Verified
Journal Article
Closed access
PDF file
RRRosa Ana Risques
Rosa Ana Risques
DPDaniel E. L. Promislow
Daniel E. L. Promislow
Among mammal species, almost all life-history traits are strongly size dependent. This size dependence even occurs at a molecular level. For example, both telomere length and telomerase expression show a size-dependent threshold. With some exceptions, species smaller than approximately 2 kg express telomerase, while species larger than that do not. Among species greater than approximately 5 kg, telomeres tend to be short—less than 25 kb—while among smaller species, some species have short and some have long telomeres. Here, we present a model to explore the role of body size-dependent trade-offs in shaping this threshold. We assume that selection favours short telomeres as a mechanism to protect against cancer. At the same time, selection favours long telomeres as a protective mechanism against DNA damage and replicative senescence. The relative importance of these two selective forces will depend on underlying intrinsic mortality and risk of cancer, both of which are size-dependent. Results from this model suggest that a cost–benefit model for the evolution of telomere length could explain phylogenetic patterns observed within the Class Mammalia. In addition, the model suggests a general conceptual framework to think about the role that body size plays in the evolution of tumour suppressor mechanisms. This article is part of the theme issue ‘Understanding diversity in telomere dynamics'.